Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD
NCT01785524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2017-07-27
Summary
The hypothesis of this proposal is that in subjects with Type II diabetes mellitus (T2D) and peripheral arterial disease (PAD) with intermittent claudication (IC), regular consumption of a high nitrate supplement which raises plasma nitrite, in conjunction with 12 weeks of supervised exercise training at the limb ischemic threshold (SET) will produce a greater clinical benefit (increases in claudication onset time \[COT\] and peak walking time \[PWT\] relative to a group with the same exercise training but supplemented with placebo .This study is essentially exploratory in nature and designed to provide us with information to adequately develop power and execute a larger study. We have previously seen benefits from nitrate supplementation on function in PAD.
Conditions
- Peripheral Arterial Disease
- Type II Diabetes Mellitus
Interventions
- DRUG
-
Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
- OTHER
-
Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH - lead OTHER
Principal Investigators
-
Jason D Allen, PhD · Duke University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-02-28
- Primary Completion
- 2014-11-30
- Completion
- 2014-11-30
Countries
- United States
Study Locations
More Related Trials
-
Carnosine for Peripheral Arterial Disease Patients
NCT05371145 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Carnosine for Peripheral Arterial Disease
NCT04870229 ·Status: COMPLETED ·Phase: PHASE2
-
NAD Supplementation and Vascular Health in PAD
NCT06534944 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)
NCT00399919 ·Status: COMPLETED ·Phase: PHASE3
-
Unacylated Ghrelin to Improve Functioning in PAD
NCT04377126 ·Status: COMPLETED ·Phase: PHASE2
-
RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)
NCT02246660 ·Status: COMPLETED ·Phase: NA
-
Evaluation of MST-188 in Acute Lower Limb Ischemia
NCT02093468 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Neo40 on PAD
NCT02934438 ·Status: UNKNOWN ·Phase: NA
-
L-Arginine in the Treatment of Peripheral Arterial Disease
NCT00284076 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
NCT00102050 ·Status: COMPLETED ·Phase: PHASE2
-
Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication
NCT01890135 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication
NCT01799057 ·Status: TERMINATED ·Phase: PHASE4
-
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
NCT03506633 ·Status: COMPLETED ·Phase: NA
-
Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02374957 ·Status: TERMINATED ·Phase: PHASE4
-
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
NCT04769206 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
NCT04800692 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NCT03743636 ·Status: COMPLETED ·Phase: PHASE3
-
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
NCT00457405 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
NCT00403494 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
NCT00117650 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
NCT01131013 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis
NCT02941419 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
NCT01256775 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
NCT01294709 ·Status: COMPLETED ·Phase: PHASE1
-
Stop Atherosclerosis in Native Diabetics Study
NCT00147251 ·Status: COMPLETED ·Phase: PHASE4